MedTrace Logo

Mesenchymal Stem Cells (MSC) for Ovarian Cancer

NCT02530047 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2019-07-18

No results posted yet for this study

Summary

The goal of this clinical research study is to find the highest tolerable dose of human mesenchymal stem cells with interferon beta (MSC-INFb) that can be given to patients with ovarian cancer and to test the safety of the MSC-INFb.

This is an investigational study. MSC-INFb infusions for ovarian cancer is investigational.

Up to 21 patients will take part in this study. All will be enrolled at MD Anderson.

Conditions

Interventions

GENETIC

MSC-INFβ

MSC-INFβ administered on an outpatient basis via intraperitoneal (IP) infusion. Starting dose: 10\^5 MSC/kg once a week for 4 treatments.

BEHAVIORAL

Questionnaires

Symptom questionnaire completed once a week for 4 weeks.

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Amanda L. Olson, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-16
Primary Completion
2019-06-13
Completion
2019-06-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02530047 on ClinicalTrials.gov